. 2014 Nov;42(11):1971–1977. doi: 10.1124/dmd.114.060285

TABLE 4.

Impact of CYP2C19 genetic variation on the association between CYP2B6 genotype and plasma steady-state OH-BUP to bupropion ratio (study 1)

	B	β	95% CI	P
OH-BUP/BUP model without CYP2C19^a
CYP2B6 NM>IM>SM	−6.48	−0.38	−11.5 to -1.43	0.01^*

OH-BUP/BUP model with CYP2C19^b
CYP2B6 NM>IM>SM	−6.88	−0.40	−12.3 to −1.51	0.01^*
CYP2C192*	−2.13	−0.09	−9.78 to 5.51	0.58
CYP2C1917*	2.50	0.11	−4.64 to 9.64	0.48

Likelihood Ratio χ²^c			1.44
P			0.49

IM, intermediate metabolizers; NM, normal metabolizers; SM, slow metabolizers (Zhu et al., 2012; Benowitz et al., 2013).

^{^a}

The association between CYP2B6 genotype and plasma steady state OH-BUP/BUP ratio.

^{^b}

The association between CYP2B6 genotype and plasma steady state OH-BUP/BUP ratio after controlling for CYP2C19 genotype.

^{^c}

Comparing the likelihood of the model without CYP2C19 versus with CYP2C19, adjusting for CYP2C19 did not significantly alter the association between CYP2B6 and plasma steady state OH-BUP/BUP ratio.

Indicates statistical significance.